Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of deferasirox in myelodysplastic syndromes.

Author: AlimenaGiuliana, BrecciaMassimo

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review discusses the use of deferasirox, an oral iron chelator, in myelodysplastic syndrome (MDS) patients who may develop organ damage due to iron overload. Deferasirox can reduce iron levels and has a relatively good safety profile, though it can cause some side effects.
Paper Details　
Original Abstract of the Article :
Transfusion dependence in myelodysplastic syndrome (MDS) patients may lead to organ damage due to accumulation of non-transferrin-bound iron with consequent increased oxidative stress. Iron chelation has been reported in retrospective studies to improve overall survival in low-risk MDS patients, but...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00277-013-1703-7

データ提供：米国国立医学図書館（NLM）

Iron Overload in Myelodysplastic Syndromes: The Role of Deferasirox

This research examines the [challenges] of [iron overload] in [myelodysplastic syndromes (MDS)], a group of [blood disorders]. The researchers reviewed the [efficacy and safety] of [deferasirox], an [oral iron chelator], in [treating MDS patients]. Their findings highlight the [potential benefits] of [deferasirox] in [reducing iron levels] and [improving hematological parameters] in [MDS patients], offering a [promising therapeutic option] for [managing this complex condition].

A New Weapon in the Fight Against Iron Overload: Deferasirox in Myelodysplastic Syndromes

This review summarizes the current knowledge regarding the [use of deferasirox] in [MDS patients]. The researchers found that [deferasirox] is [effective in reducing serum ferritin levels] and [labile plasma iron] in [MDS patients], both in those who are [chelation naïve] and those who have been [previously treated]. Furthermore, [deferasirox] has demonstrated [a favorable safety profile], with [common side effects] being [generally manageable].

The Desert of Blood Disorders: Finding Solutions

This research reminds me of a desert landscape, where [scarce resources] can lead to [challenges] for [survival]. Just as a [desert ecosystem] might struggle with [limited water availability], [MDS patients] can face [iron overload] due to [disrupted blood cell production]. This review provides a glimmer of hope, suggesting that [deferasirox] could be a valuable tool in the [fight against iron overload], helping to [restore balance] and [improve quality of life] for [MDS patients].

Dr. Camel's Conclusion

This review summarizes the results of different studies testing the safety and efficacy of deferasirox in MDS patients. Deferasirox is a potent iron chelator that has shown promise in reducing serum ferritin levels and labile plasma iron, improving hematological parameters, and having an acceptable safety profile. Further research is needed to determine the optimal use of deferasirox in MDS patients and to assess its long-term effects.

Date :
  1. Date Completed 2013-08-16
  2. Date Revised 2022-03-21
Further Info :

Pubmed ID

23417759

DOI: Digital Object Identifier

10.1007/s00277-013-1703-7

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.